MoonLake Immunotherapeutics (MLTX) Cash from Investing Activities (2021 - 2026)

MoonLake Immunotherapeutics' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $98000.0 for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 99.83% year-over-year to $98000.0 in Q1 2026; TTM through Mar 2026 was $146.8 million, a 221.82% increase from a year earlier, with the FY2025 full-year figure at $203.0 million, up 198.73% from the prior year.
• Cash from Investing Activities improved to $98000.0 in Q1 2026 per MLTX's latest filing, from -$29.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $116.9 million in Q4 2023 and bottomed at -$174.4 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is $98000.0 (2026), against an average of -$3.5 million.
• Across the five-year window, Cash from Investing Activities sank 362386.24% in 2022 and jumped 633802550.0% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $9.9 million in 2022, then jumped by 1080.3% to $116.9 million in 2023, then plunged by 226.07% to -$147.3 million in 2024, then jumped by 79.7% to -$29.9 million in 2025, then jumped by 100.33% to $98000.0 in 2026.
• Per Business Quant, the three latest MLTX Cash from Investing Activities figures stand at $98000.0 (Q1 2026), -$29.9 million (Q4 2025), and $88.4 million (Q3 2025).